PULMATRIX, INC. Proceeds from Notes Payable
PULMATRIX, INC. (PULM) reported Proceeds from Notes Payable of $4.46 million for the 12-month period ending 2015-12-31, per its 10-K filed 2017-03-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2017-03-10
- PULMATRIX, INC. proceeds from notes payable for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- PULMATRIX, INC. proceeds from notes payable for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- PULMATRIX, INC. proceeds from notes payable for the quarter ending 2015-06-30 was -$43.00K.
- PULMATRIX, INC. proceeds from notes payable for the quarter ending 2015-03-31 was $4.50M.
- PULMATRIX, INC. proceeds from notes payable for fiscal 2015 was $4.46M, a 47.41% decline from fiscal 2014.
- PULMATRIX, INC. proceeds from notes payable for fiscal 2014 was $8.47M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $0.00 derived: sum of 2 quarters · filed 2017-03-10 | -$43.00K derived: sum of 3 quarters · filed 2017-03-10 | $4.46M 10-K · filed 2017-03-10 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$43.00K derived: sum of 2 quarters · filed 2016-11-04 | $4.46M 10-Q · filed 2016-11-04 | $6.06M derived: sum of 4 quarters · filed 2016-11-04 |
| 2015-06-30 | -$43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $4.46M 10-Q · filed 2016-08-04 | $6.06M derived: sum of 3 quarters · filed 2016-08-04 | $7.88M derived: sum of 4 quarters · filed 2016-08-04 |
| 2015-03-31 | $4.50M 10-Q · filed 2016-05-05 | $6.10M derived: sum of 2 quarters · filed 2016-05-05 | $7.92M derived: sum of 3 quarters · filed 2016-05-05 | |
| 2014-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $3.42M derived: sum of 2 quarters · filed 2016-03-10 | $8.47M 10-K · filed 2016-03-10 | |
| 2014-09-30 | $1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $6.88M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $5.05M 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |